INTRODUCTION
Pancreatic cancer has one of the worst prognosis among all malignancies and is projected to become the second leading cause of cancer-related deaths in certain regions. It is the fourth leading cause of cancer-related deaths worldwide.
pancreatic cancer has a low 5-year survival rate of 2% to 9%, which remains consistent across both high-income and low- to middle-income countries. This survival rate also varies by location and country, but it never exceeds 10%.
Adenocarcinoma is the most common type of pancreatic cancer . The name 'silent killer' has been given to this cancer because it progresses silently, has late clinical signs, and grows rapidly.
.
AIM OF THE WORK
The main goal of our study was to assess the recent updates in the role of MDCT in prediction of resectability of pancreatic cancer
SUBJECTS AND METHODS
Target population:
The study was carried out on 42 patients with approved manifestations of cancer pancreas who admitted to Alexandria main university hospital and Gamal Abdel Naser insurance hospital for diagnosis and management.
Before CT imaging, all individuals were subjected to:
I. Informed written consent.
II. Full history and clinical examination.
III. General and abdominal examinations by the referral clinician.
IV. Laboratory investigations.
V. Imaging techniques: